Shareholder Alert: Ademi LLP investigates whether POINT Biopharma Global, Inc. has obtained a Fair Price in its transaction with Eli Lilly

MILWAUKEE, Oct. 3, 2023 /PRNewswire/ -- Ademi LLP is investigating POINT (Nasdaq: PNT) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly.

Click here to learn how to join the action https://www.ademilaw.com/case/point-biopharma-global-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, POINT stockholders are expected to receive only $12.50 per share in cash (an aggregate of approximately $1.4 billion). The transaction agreement unreasonably limits competing transactions for POINT by imposing a significant penalty if POINT accepts a competing bid. POINT insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of POINT's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own POINT common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/point-biopharma-global-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                                    
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-point-biopharma-global-inc-has-obtained-a-fair-price-in-its-transaction-with-eli-lilly-301945723.html

SOURCE Ademi LLP